<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32676760</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Validation of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale in Poland and its reliability in conditions of the medical experiment.</ArticleTitle><Pagination><StartPage>943</StartPage><EndPage>949</EndPage><MedlinePgn>943-949</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-020-04565-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) is a basic tool for monitoring disease progression in amyotrophic lateral sclerosis (ALS). This study analyses the reliability of the Polish version of the ALSFRS-R as a tool to assess the health condition of patients with ALS and presents experience related to the use of this tool in monitoring the effects of experimental medical therapy.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The scale questionnaire was translated using the cross-translation method. The final tool was used by researcher, who was conducting the interview directly by telephone with patients and their caregivers and additionally compared with neurologopedic measurement. The health status of 60 patients was assessed between 4 and 7 times, which gives a total of 327 observations. Mean patient's age was 57.5&#x2009;&#xb1;&#x2009;8.6. The division by sex was 23/35 (female/male). Patients' health status and severity of symptoms varied. Statistical analysis was performed using explanatory factor analysis and Cronbach's alpha.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">Validation of the Polish version of the ALSFRS-R supports the reliability and internal consistency of scale. The scale proved also to be a proper tool for monitoring the course of the experimental medical therapy for patients with ALS. However, a qualitative evaluation revealed certain weaknesses of the scale, resulting from a different understanding of the functional assessment by the patient and by the medical specialist and cultural differences.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Although ALSFRS-R is a reliable enough for monitoring patient health, it seems reasonable to pay attention to some difficult points of the questionnaire and its improvement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maksymowicz</LastName><ForeName>Stanis&#x142;aw</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6606-9575</Identifier><AffiliationInfo><Affiliation>Department of Psychology and Sociology of Health and Public Health, School of Public Health, Collegium Medicum of the University of Warmia and Mazury, Olsztyn, Poland. stanislaw.maksymowicz@uwm.edu.pl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instytut Terapii Kom&#xf3;rkowych S.A., Olsztyn, Poland. stanislaw.maksymowicz@uwm.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuko&#x142;owicz</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Polish Economic Institute, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siwek</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Instytut Terapii Kom&#xf3;rkowych S.A., Olsztyn, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Collegium Medicum of the University of Warmia and Mazury, Olsztyn, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Clinical Hospital, Olsztyn, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rakowska</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Instytut Terapii Kom&#xf3;rkowych S.A., Olsztyn, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Clinical Hospital, Olsztyn, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011044" MajorTopicYN="N" Type="Geographic">Poland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALSFRS-R</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Medical experiment</Keyword><Keyword MajorTopicYN="N">Validation</Keyword></KeywordList><CoiStatement>The authors declare that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32676760</ArticleId><ArticleId IdType="pmc">PMC7870618</ArticleId><ArticleId IdType="doi">10.1007/s10072-020-04565-5</ArticleId><ArticleId IdType="pii">10.1007/s10072-020-04565-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gordon PH. Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management. CNS Drugs. 2011;25:1&#x2013;15. doi: 10.2165/11586000-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11586000-000000000-00000</ArticleId><ArticleId IdType="pubmed">21128691</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A, et al. Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany. J Neurol. 2018;265:774&#x2013;782. doi: 10.1007/s00415-018-8735-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8735-9</ArticleId><ArticleId IdType="pubmed">29392461</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Do Y, Park J, et al. Under-recognized primary spontaneous pneumothorax in ALS: a multicenter retrospective study. Neurol Sci. 2019;40:2509&#x2013;2514. doi: 10.1007/s10072-019-03989-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03989-y</ArticleId><ArticleId IdType="pubmed">31267304</ArticleId></ArticleIdList></Reference><Reference><Citation>Armon C. Motor neuron disease. In: Gorelick PB AM, editor. Handbook of neuroepidemiology. NYC: Marcel Dekker; 1994. pp. 407&#x2013;454.</Citation></Reference><Reference><Citation>Clarke C, Howard R, Rossor M, Shorvon S (2016) Neurology: a Queen Square textbook. Wiley</Citation></Reference><Reference><Citation>Russ KB, Phillips MC, Wilcox CM, Peter S. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis. Am J Med Sci. 2015;350(2):95&#x2013;97. doi: 10.1097/MAJ.0000000000000517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAJ.0000000000000517</ArticleId><ArticleId IdType="pubmed">26135224</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB. Clinical measures of disease progression in amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12(2):384&#x2013;393. doi: 10.1007/s13311-014-0331-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0331-9</ArticleId><ArticleId IdType="pmc">PMC4404434</ArticleId><ArticleId IdType="pubmed">25582382</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Kim S, Park D, et al. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Neurol Sci. 2020;41:119&#x2013;123. doi: 10.1007/s10072-019-04055-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04055-3</ArticleId><ArticleId IdType="pmc">PMC7223963</ArticleId><ArticleId IdType="pubmed">31471712</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Barczewska M, et al. Safety of intrathecal injection of Wharton&#x2019;s jelly-derived mesenchymal stem cells in amyotrophic lateral sclerosis therapy. Neural Regen Res. 2019;14(2):313. doi: 10.4103/1673-5374.243723.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.243723</ArticleId><ArticleId IdType="pmc">PMC6301165</ArticleId><ArticleId IdType="pubmed">30531015</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol. 1987;22(3):328&#x2013;333. doi: 10.1002/ana.410220308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410220308</ArticleId><ArticleId IdType="pubmed">3118763</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker LA, Schr&#xf6;der CD, van Es MA, Westers P, Visser-Meily JMA, van den Berg LH. Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model. J Neurol. 2017;264(7):1413&#x2013;1420. doi: 10.1007/s00415-017-8538-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8538-4</ArticleId><ArticleId IdType="pmc">PMC5502060</ArticleId><ArticleId IdType="pubmed">28608303</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedes K, Pereira C, Pavan K, Valerio BCO. Cross-cultural adaptation and validation of Als functional rating scale-revised in Portuguese language. Arq Neuropsiquiatr. 2010;68(1):44&#x2013;47. doi: 10.1590/S0004-282X2010000100010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0004-282X2010000100010</ArticleId><ArticleId IdType="pubmed">20339651</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulla S, Vielhaber S, K&#xf6;rner S, Machts J, Heinze HJ, Dengler R, Petri S. Validation of the German version of the extended ALS functional rating scale as a patient-reported outcome measure. J Neurol. 2013;260(9):2242&#x2013;2255. doi: 10.1007/s00415-013-6955-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-013-6955-6</ArticleId><ArticleId IdType="pubmed">23736973</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacci ED, Staniewska D, Coyne KS, Boyer S, White LA, Zach N, Cedarbaum JM, The Pooled Resource Open-Access ALS Clinical Trials Consortium Item response theory analysis of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised in the Pooled Resource Open-Access ALS Clinical Trials database. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3&#x2013;4):157&#x2013;167. doi: 10.3109/21678421.2015.1095930.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1095930</ArticleId><ArticleId IdType="pubmed">26473473</ArticleId></ArticleIdList></Reference><Reference><Citation>Wicks P, Massagli MP, Wolf C, Heywood J. Measuring function in advanced ALS: validation of ALSFRS-EX extension items. Eur J Neurol. 2009;16(3):353&#x2013;359. doi: 10.1111/j.1468-1331.2008.02434.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2008.02434.x</ArticleId><ArticleId IdType="pubmed">19364363</ArticleId></ArticleIdList></Reference><Reference><Citation>Makkonen T, Ruottinen H, Puhto R, Helminen M, Palmio J. Speech deterioration in amyotrophic lateral sclerosis (ALS) after manifestation of bulbar symptoms. Int J Lang Commun Disord. 2018;53(2):385&#x2013;392. doi: 10.1111/1460-6984.12357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1460-6984.12357</ArticleId><ArticleId IdType="pubmed">29159848</ArticleId></ArticleIdList></Reference><Reference><Citation>Beukelman D, Fager S, Nordness A. Communication support for people with ALS. Neurol Res Int. 2011;2011:714693. doi: 10.1155/2011/714693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/714693</ArticleId><ArticleId IdType="pmc">PMC3096454</ArticleId><ArticleId IdType="pubmed">21603029</ArticleId></ArticleIdList></Reference><Reference><Citation>Che&#x142;stowska B, Ku&#x17a;ma-Kozakiewicz M. Biochemical parameters in determination of nutritional status in amyotrophic lateral sclerosis. Neurol Sci. 2020;41:1115&#x2013;1124. doi: 10.1007/s10072-019-04201-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04201-x</ArticleId><ArticleId IdType="pubmed">31897946</ArticleId></ArticleIdList></Reference><Reference><Citation>Panebianco M, Marchese-Ragona R, Masiero S, Restivo DA (2020) Dysphagia in neurological diseases: a literature review. Neurol Sci. 10.1007/s10072-020-04495-2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7567719</ArticleId><ArticleId IdType="pubmed">32506360</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology. 2002;59(1):99&#x2013;103. doi: 10.1212/WNL.59.1.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.59.1.99</ArticleId><ArticleId IdType="pubmed">12105314</ArticleId></ArticleIdList></Reference><Reference><Citation>Enderby P. Frenchay dysarthria assessment. Br J Disord Commun. 1980;15(3):165&#x2013;173. doi: 10.3109/13682828009112541.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13682828009112541</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantopoulos K, Zamba-Papanicolaou E, Christodoulou K. Quantification of dysarthr&#x3bf;phonia in a Cypriot family with autosomal recessive hereditary spastic paraplegia associated with a homozygous SPG11 mutation. Neurol Sci. 2018;39:1547&#x2013;1550. doi: 10.1007/s10072-018-3453-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3453-8</ArticleId><ArticleId IdType="pubmed">29804168</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlukowska W, et al. Comparative assessment and monitoring of deterioration of articulatory organs using subjective and objective tools among patients with amyotrophic lateral sclerosis. BMC Neurol. 2019;19(1):241. doi: 10.1186/s12883-019-1484-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-019-1484-2</ArticleId><ArticleId IdType="pmc">PMC6800986</ArticleId><ArticleId IdType="pubmed">31629403</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Miller RG, Moore DH. ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(Suppl 1):90&#x2013;93. doi: 10.1080/17434470410019906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17434470410019906</ArticleId><ArticleId IdType="pubmed">15512883</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Mareschi K, Ferrero I, Vassallo E, Oliveri G, Boccaletti R, Testa L, Livigni S, Fagioli F. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Neurol Res. 2006;28:523&#x2013;526. doi: 10.1179/016164106X116791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/016164106X116791</ArticleId><ArticleId IdType="pubmed">16808883</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Fagioli F, Boccaletti R, Mareschi K, Oliveri G, Olivieri C, Pastore I, Marasso R, Madon E. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph Lateral Scler Other Mot Neuron Disord. 2003;4:158&#x2013;161. doi: 10.1080/14660820310014653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820310014653</ArticleId><ArticleId IdType="pubmed">13129802</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh KW, Moon C, Kim HY, Oh SI, Park J, Lee JH, Chang IY, Kim KS, Kim SH. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl Med. 2015;4:590&#x2013;597. doi: 10.5966/sctm.2014-0212.</Citation><ArticleIdList><ArticleId IdType="doi">10.5966/sctm.2014-0212</ArticleId><ArticleId IdType="pmc">PMC4449093</ArticleId><ArticleId IdType="pubmed">25934946</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HY, et al. Efficacy and safety of autologous bone marrow-derived mesenchymal stem cell treatment in patients with amyotrophic lateral sclerosis. J Korean Neurol Assoc. 2009;27(2):163&#x2013;169.</Citation></Reference><Reference><Citation>Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky O, Melamed E, Karussis D. Safety and clinical effects of Mesenchymal stem cells secreting Neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol. 2016;73:337&#x2013;344. doi: 10.1001/jamaneurol.2015.4321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.4321</ArticleId><ArticleId IdType="pubmed">26751635</ArticleId></ArticleIdList></Reference><Reference><Citation>Siwek T, et al. Mesenchymal stem cell (MSC) transplantation in patients with amyotrophic lateral sclerosis (ALS): is there a &#x2018;responder population&#x2019;? J Neurol Neurosci. 2018;09(03):1&#x2013;6. doi: 10.21767/2171-6625.1000260.</Citation><ArticleIdList><ArticleId IdType="doi">10.21767/2171-6625.1000260</ArticleId></ArticleIdList></Reference><Reference><Citation>Bujang MA, Omar ED, Baharum NA. A review on sample size determination for Cronbach&#x2019;s alpha test: a simple guide for researchers. Malays J Med Sci. 2018;25(6):85&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6422571</ArticleId><ArticleId IdType="pubmed">30914882</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, Levy G, Montes J, Buchsbaum R, Barsdorf AI, Battista V, Arbing R, Gordon PH, Mitsumoto H, Levin B, Thompson JLP, Kaufmann P, Levy G, Montes J, Buchsbaum R, Barsdorf AI, Battista V, Arbing R, Gordon PH, Mitsumoto H, Levin B, Thompson JLP. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph Lateral Scler. 2007;8(1):42&#x2013;46. doi: 10.1080/17482960600888156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600888156</ArticleId><ArticleId IdType="pubmed">17364435</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannino M, Cellura E, Grimaldi G, Volanti P, Piccoli F, La Bella V. Telephone follow-up for patients with amyotrophic lateral sclerosis. Eur J Neurol. 2007;14(1):79&#x2013;84. doi: 10.1111/j.1468-1331.2006.01559.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2006.01559.x</ArticleId><ArticleId IdType="pubmed">17222118</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F, Mora G, Giordano A, Volanti P, Chi&#xf2; A. Evidence of multidimensionality in the ALSFRS-R scale: a critical appraisal on its measurement properties using Rasch analysis journal of neurology. Neurosurg Psychiatry. 2013;84:1340&#x2013;1345. doi: 10.1136/jnnp-2012-304701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304701</ArticleId><ArticleId IdType="pubmed">23516308</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>